Agency Information Collection Activities; Proposed eCollection, eComments Requested; Revision of a Currently Approved Collection; The National Forensic Laboratory Information System Collection of Analysis Data, 63067-63068 [2021-24780]

Download as PDF Federal Register / Vol. 86, No. 217 / Monday, November 15, 2021 / Notices 63067 Final adjusted 2021 quotas Basic class (g) L-methamphetamine ............................................................................................................................................................................ Meperidine ........................................................................................................................................................................................... Meperidine Intermediate-A .................................................................................................................................................................. Meperidine Intermediate-B .................................................................................................................................................................. Meperidine Intermediate-C .................................................................................................................................................................. Metazocine ........................................................................................................................................................................................... Methadone (for sale) ........................................................................................................................................................................... Methadone Intermediate ...................................................................................................................................................................... Methamphetamine ............................................................................................................................................................................... D-methamphetamine (for conversion) ................................................................................................................................................. D-methamphetamine (for sale) ............................................................................................................................................................ Methylphenidate (for conversion) ........................................................................................................................................................ Methylphenidate (for sale) ................................................................................................................................................................... Metopon ............................................................................................................................................................................................... Moramide-intermediate ........................................................................................................................................................................ Morphine (for conversion) .................................................................................................................................................................... Morphine (for sale) .............................................................................................................................................................................. Nabilone ............................................................................................................................................................................................... Norfentanyl ........................................................................................................................................................................................... Noroxymorphone (for conversion) ....................................................................................................................................................... Noroxymorphone (for sale) .................................................................................................................................................................. Oliceridine ............................................................................................................................................................................................ Opium (powder) ................................................................................................................................................................................... Opium (tincture) ................................................................................................................................................................................... Oripavine .............................................................................................................................................................................................. Oxycodone (for conversion) ................................................................................................................................................................ Oxycodone (for sale) ........................................................................................................................................................................... Oxymorphone (for conversion) ............................................................................................................................................................ Oxymorphone (for sale) ....................................................................................................................................................................... Pentobarbital ........................................................................................................................................................................................ Phenazocine ........................................................................................................................................................................................ Phencyclidine ....................................................................................................................................................................................... Phenmetrazine ..................................................................................................................................................................................... Phenylacetone ..................................................................................................................................................................................... Piminodine ........................................................................................................................................................................................... Racemethorphan ................................................................................................................................................................................. Racemorphan ...................................................................................................................................................................................... Remifentanil ......................................................................................................................................................................................... Secobarbital ......................................................................................................................................................................................... Sufentanil ............................................................................................................................................................................................. Tapentadol ........................................................................................................................................................................................... Thebaine .............................................................................................................................................................................................. 587,229 856,695 30 30 30 15 25,619,700 27,673,600 50 485,020 40,000 15,300,000 57,438,334 25 25 3,376,696 26,505,995 62,000 25 22,044,741 376,000 22,500 250,000 530,837 33,010,750 620,887 57,110,032 28,204,371 563,174 30,766,670 25 35 25 6,100,000 25 5 5 3,000 172,100 4,000 13,447,541 57,137,944 List I Chemicals Ephedrine (for conversion) .................................................................................................................................................................. Ephedrine (for sale) ............................................................................................................................................................................. Phenylpropanolamine (for conversion) ................................................................................................................................................ Phenylpropanolamine (for sale) ........................................................................................................................................................... Pseudoephedrine (for conversion) ...................................................................................................................................................... Pseudoephedrine (for sale) ................................................................................................................................................................. khammond on DSKJM1Z7X2PROD with NOTICES The Administrator further proposes that APQ for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero. Anne Milgram, Administrator. [FR Doc. 2021–24921 Filed 11–10–21; 4:15 pm] BILLING CODE 4410–09–P [OMB Number 1117–0034] Agency Information Collection Activities; Proposed eCollection, eComments Requested; Revision of a Currently Approved Collection; The National Forensic Laboratory Information System Collection of Analysis Data Drug Enforcement Administration, Department of Justice. ACTION: 30-Day Notice. AGENCY: VerDate Sep<11>2014 16:42 Nov 12, 2021 Jkt 256001 PO 00000 Frm 00084 Fmt 4703 Sfmt 4703 The Department of Justice (DOJ), Drug Enforcement Administration (DEA), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. This proposed information collection was previously published in the Federal Register at 86 FR 47523 on August 25, 2021, allowing for a 60 day comment period. No comments were received. SUMMARY: DEPARTMENT OF JUSTICE 100 4,136,000 14,878,320 16,690,000 1,000 174,246,000 E:\FR\FM\15NON1.SGM 15NON1 63068 Federal Register / Vol. 86, No. 217 / Monday, November 15, 2021 / Notices Comments are encouraged and will be accepted for an additional 30 days until December 15, 2021. FOR FURTHER INFORMATION CONTACT: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/ PRAMain. Find this particular information collection by selecting ‘‘Currently under 30-day Review—Open for Public Comments’’ or by using the search function. SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; —Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; —Evaluate whether and if so how the quality, utility, and clarity of the information proposed to be collected can be enhanced; and —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other forms of information technology, e.g., permitting electronic submission of responses. DATES: khammond on DSKJM1Z7X2PROD with NOTICES Overview of This Information Collection 1. Type of Information Collection: Revision of a currently approved collection. 2. Title of the Form/Collection: The National Forensic Laboratory Information System Collection of Analysis Data. 3. The agency form number, if any, and the applicable component of the Department sponsoring the collection: There are no form numbers associated with this collection. The applicable component within the Department of Justice is the Drug Enforcement Administration, Diversion Control Division. 4. Affected public who will be asked or required to respond, as well as a brief abstract: Affected public (Primary): Forensic Science Laboratory Management. VerDate Sep<11>2014 16:42 Nov 12, 2021 Jkt 256001 Affected public (Other): None. Abstract: This collection provides the Drug Enforcement Administration (DEA) with a national database on analyzed drug evidence from nonfederal laboratories. Information from this database is combined with the other existing databases to develop more accurate, up-to-date information on abused drugs. This database represents a voluntary, cooperative effort on the part of participating laboratories to provide a centralized source of analyzed drug data. 5. An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: DEA estimates that 2,640 persons annually for this collection at 2.2015 hour per respondent, for an annual burden of 5,812 hours. 6. An estimate of the total public burden (in hours) associated with the proposed collection: DEA estimates that this collection takes 5,812 annual burden hours. If additional information is required please contact: Melody Braswell, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Two Constitution Square, 145 N Street NE, Suite 3E.405B, Washington, DC 20530. Dated: November 8, 2021. Melody Braswell, Department Clearance Officer for PRA, U.S. Department of Justice. [FR Doc. 2021–24780 Filed 11–12–21; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF LABOR Employment and Training Administration Federal-State Unemployment Compensation Program: Certifications for 2021 Under the Federal Unemployment Tax Act Employment and Training Administration, Department of Labor. ACTION: Notice. AGENCY: The Secretary of Labor signed the annual certifications under the Federal Unemployment Tax Act, 26 U.S.C. 3301 et seq., thereby enabling employers who make contributions to state unemployment funds to obtain certain credits against their liability for the federal unemployment tax. By letter, the certifications were transmitted to the Secretary of the Treasury. The letter and certifications are printed below. SUMMARY: PO 00000 Frm 00085 Fmt 4703 Sfmt 4703 Signed in Washington, DC, October 31, 2021. Angela Hanks, Acting Assistant Secretary, Employment and Training. The Honorable Janet L. Yellen Secretary of the Treasury Department of the Treasury 1500 Pennsylvania Avenue NW Washington, DC 20220 Dear Secretary Yellen: Enclosed are an original and a copy of each of two separate certifications regarding state unemployment compensation laws pursuant to the Federal Unemployment Tax Act, for the 12-month period ending on October 31, 2021. One certification is with respect to the ‘‘normal’’ federal unemployment tax credit under Section 3304 of the Internal Revenue Code of 1986 (IRC), and the other certification is with respect to the ‘‘additional’’ tax credit under Section 3303 of the IRC. Both certifications list all 53 states. Sincerely, MARTIN J. WALSH CERTIFICATION OF STATES TO THE SECRETARY OF THE TREASURY PURSUANT TO SECTION 3304(c) OF THE INTERNAL REVENUE CODE OF 1986 In accordance with the provisions of Section 3304(c) of the Internal Revenue Code of 1986 (26 U.S.C. 3304(c)), I hereby certify the following named states to the Secretary of the Treasury for the 12-month period ending on October 31, 2021, in regard to the unemployment compensation laws of those states, which heretofore have been approved under the Federal Unemployment Tax Act: Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan E:\FR\FM\15NON1.SGM 15NON1

Agencies

[Federal Register Volume 86, Number 217 (Monday, November 15, 2021)]
[Notices]
[Pages 63067-63068]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-24780]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

[OMB Number 1117-0034]


Agency Information Collection Activities; Proposed eCollection, 
eComments Requested; Revision of a Currently Approved Collection; The 
National Forensic Laboratory Information System Collection of Analysis 
Data

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: 30-Day Notice.

-----------------------------------------------------------------------

SUMMARY: The Department of Justice (DOJ), Drug Enforcement 
Administration (DEA), will be submitting the following information 
collection request to the Office of Management and Budget (OMB) for 
review and approval in accordance with the Paperwork Reduction Act of 
1995. This proposed information collection was previously published in 
the Federal Register at 86 FR 47523 on August 25, 2021, allowing for a 
60 day comment period. No comments were received.

[[Page 63068]]


DATES:  Comments are encouraged and will be accepted for an additional 
30 days until December 15, 2021.

FOR FURTHER INFORMATION CONTACT:  Written comments and recommendations 
for the proposed information collection should be sent within 30 days 
of publication of this notice to www.reginfo.gov/public/do/PRAMain. 
Find this particular information collection by selecting ``Currently 
under 30-day Review--Open for Public Comments'' or by using the search 
function.

SUPPLEMENTARY INFORMATION: 
    Written comments and suggestions from the public and affected 
agencies concerning the proposed collection of information are 
encouraged. Your comments should address one or more of the following 
four points:
--Evaluate whether the proposed collection of information is necessary 
for the proper performance of the functions of the agency, including 
whether the information will have practical utility;
--Evaluate the accuracy of the agency's estimate of the burden of the 
proposed collection of information, including the validity of the 
methodology and assumptions used;
--Evaluate whether and if so how the quality, utility, and clarity of 
the information proposed to be collected can be enhanced; and
--Minimize the burden of the collection of information on those who are 
to respond, including through the use of appropriate automated, 
electronic, mechanical, or other forms of information technology, e.g., 
permitting electronic submission of responses.

Overview of This Information Collection

    1. Type of Information Collection: Revision of a currently approved 
collection.
    2. Title of the Form/Collection: The National Forensic Laboratory 
Information System Collection of Analysis Data.
    3. The agency form number, if any, and the applicable component of 
the Department sponsoring the collection: There are no form numbers 
associated with this collection. The applicable component within the 
Department of Justice is the Drug Enforcement Administration, Diversion 
Control Division.
    4. Affected public who will be asked or required to respond, as 
well as a brief abstract:
    Affected public (Primary): Forensic Science Laboratory Management.
    Affected public (Other): None.
    Abstract: This collection provides the Drug Enforcement 
Administration (DEA) with a national database on analyzed drug evidence 
from non-federal laboratories. Information from this database is 
combined with the other existing databases to develop more accurate, 
up-to-date information on abused drugs. This database represents a 
voluntary, cooperative effort on the part of participating laboratories 
to provide a centralized source of analyzed drug data.
    5. An estimate of the total number of respondents and the amount of 
time estimated for an average respondent to respond: DEA estimates that 
2,640 persons annually for this collection at 2.2015 hour per 
respondent, for an annual burden of 5,812 hours.
    6. An estimate of the total public burden (in hours) associated 
with the proposed collection: DEA estimates that this collection takes 
5,812 annual burden hours.
    If additional information is required please contact: Melody 
Braswell, Department Clearance Officer, United States Department of 
Justice, Justice Management Division, Policy and Planning Staff, Two 
Constitution Square, 145 N Street NE, Suite 3E.405B, Washington, DC 
20530.

    Dated: November 8, 2021.
Melody Braswell,
Department Clearance Officer for PRA, U.S. Department of Justice.
[FR Doc. 2021-24780 Filed 11-12-21; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.